Hepatitis and liver cancer a national strategy for prevention and control of hepatitis B and C.
- Washington. DC | National Academy of Sciences | 2010.
- 253 Pages Includes bibliographical references and index.
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care.
Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood.
Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.
978-0-309-14628-9
= ACIP acute HBV infection acute hepatitis adults American Journal anti-HBs antibody Asian at-risk populations CDC Centers for Disease chronic HBV infection chronic hepatitis chronically infected Control and Prevention cost-effective develop Disease Control dose Epidemiology evaluation federal followup foreign-born funding guidelines Hagan Harm Reduction HBsAg HBsAg-positive HBV and HCV HCC HCV infection health departments hepa hepatitis B surface hepatitis B vaccination hepatitis C virus hepatocellular carcinoma Hepatology high-risk HIV identify IDUs incarcerated incidence infants infected with HBV Infectious Diseases injection drug users injection-drug Jarlais lamivudine liver cancer liver disease medical management Medicine Morbidity and Mortality Mortality Weekly Report National Pacific Islander patients perinatal hepatitis pregnant women prevention and control programs Recommendations risk factors seroconversion sexually transmitted disease STD clinics strategies surveillance system syringes tested for HBV tion treatment U.S. Census Bureau United vaccination coverage vaccination rates vaccine series viral hepatitis prevention viral hepatitis services virus infection
--Hepatitis B—complications—United States. --Hepatitis B—prevention & control—United States. --Hepatitis C—complications—United States. --Hepatitis C— prevention & control—United States. --Liver Neoplasms—prevention & control—United States. -- Viral Hepatitis Vaccines—therapeutic use—United States.